BriefMD

Specialties / Dermatology

New Dermatology research.

The strongest recent Dermatology papers on PubMed, ranked by study design, topic and journal, with the same summaries subscribers get.

  1. randomized trial

    Thulium laser-assisted delivery of growth factors for treating androgenetic alopecia - a randomized, controlled, clinical study

    Nguyen L, Schneider SW, Herberger K. Lasers Med Sci. Oct 2026.

    Findings
    Hair density improvements reached 25.6 ± 7.0 % with triple therapy and 22.7 ± 3.4 % with dual therapy, compared to 4.9 ± 9.2 % in the EBD-only group. Hair thickness also improved in both serum groups.
    Bottom line
    Laser-assisted delivery of growth factors enhances hair density (up to 25.6 ± 7.0 %) in patients with androgenetic alopecia.

    PubMed, PMID 42911445

  2. randomized trial, 125 patients

    Ociperlimab and tislelizumab in advanced esophageal squamous cell carcinoma (AdvanTIG-203): a phase II study

    Wang F, Lin CY, Sun JM, et al. Nat Commun. Sep 2026.

    Findings
    In this phase II trial, 125 patients were allocated to two arms, with 62 receiving treatment A and 63 receiving treatment B.
    Bottom line
    The study enrolled 125 participants, split into groups of 62 and 63.

    PubMed, PMID 42901884

  3. retrospective cohort

    Novel Potential Histologic Clues to Mechanical Alopecia: A Comparative Study of Traction Alopecia, Trichotillomania, and Approximately Age/Gender Matched Controls

    Ting Z, Spear L, Smith J, et al. J Cutan Pathol. Oct 2026.

    Findings
    In a blinded study of 16 traction alopecia and 9 trichotillomania cases versus 15 controls, warped sebaceous lobules were specific to TA (p = 0.0002), inner root sheath collapse to TTM (p < 0.0002), and lateral impingement was common to both (p < 0.0001).
    Bottom line
    Distinct histologic patterns help differentiate traction alopecia from trichotillomania.

    PubMed, PMID 42899449

  4. prospective cohort, 302 patients

    Gastrointestinal Side Effects of Low-Dose Oral Minoxidil in Patients with Alopecia: An Underrecognized Association

    Soares J, Martínez-Sellés M, Soares RO. Dermatol Pract Concept. Jul 2026.

    Findings
    In 302 alopecia patients taking low-dose oral minoxidil, 22 (7.3%) experienced gastrointestinal side effects. Symptoms correlated with higher minoxidil doses (2.7 ± 1.6 vs 1.3 ± 1.2 mg, P = 0.01) and were more frequent in males (15.5% vs 4.1%, P < 0.001) and concurrent vasodilator users (25.6% vs 4.6%, P < 0.001).
    Bottom line
    Low-dose oral minoxidil can cause dose-dependent gastrointestinal side effects, especially in males and patients taking concomitant vasodilators.

    PubMed, PMID 42858418

  5. phase ii trial, 200 patients

    Efficacy and safety of QY201, an oral dual Janus kinase 1/tyrosine kinase 2 inhibitor, in adults with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 2 dose-finding trial

    Wang T, Li J, Liang Y, et al. J Am Acad Dermatol. Oct 2026.

    Findings
    In a 200‑patient phase‑2 RCT, QY201 10 mg BID produced an 84.7% EASI‑75 response at week 12 versus 18.5% with placebo (P<0.0001). Higher doses also improved IGA scores (up to 71.3% vs 12.4% placebo) and showed TEAEs in 75–90% of participants.
    Bottom line
    QY201 10 mg BID markedly increases EASI‑75 response (84.7% vs 18.5% placebo) with a safety profile comparable to lower doses.

    PubMed, PMID 42901423

  6. randomized trial

    Long-term efficacy of lebrikizumab in treating head, neck and face involvement in patients with moderate-to-severe atopic dermatitis

    Chovatiya R, de Bruin-Weller M, Alexis A, et al. J Dermatolog Treat. Dec 2026.

    Findings
    In week‑16 responders, 94.8% maintained HN EASI‑75, 82.9% HN EASI‑90, and 85.3% HN EASI‑100 at week 152 (3 years).
    Bottom line
    Lebrikizumab provides durable HN‑area control with >94% retaining EASI‑75 at 3 years.

    PubMed, PMID 42895209

  7. randomized trial, 70 patients

    Adjuvant 904 nm Gallium Arsenide Laser Therapy Enhances Healing and Reduces Bacterial Burden in Chronic Wounds: A Randomized Controlled Trial

    Baracho VDS, Silva NCD, Godinho LF, et al. Wound Repair Regen. Jan 2026.

    Findings
    In 70 patients, the AL group had a 53% reduction in wound area, while the PL group had a 9% reduction (p < 0.001).
    Bottom line
    904 nm GaAs laser therapy accelerates chronic wound healing, reduces bacterial load, and improves tissue remodeling, supporting its use as an adjunct to standard care.

    PubMed, PMID 42921882

  8. meta-analysis, 3,733,499 patients

    Fertility Treatment and Risk of Melanoma: A Certainty-Rated Systematic Review and Meta-Analysis of 3,733,499 Women

    Stylianakis D, Solinas C, Petrelli F, et al. Eur J Clin Invest. Nov 2026.

    Findings
    In a systematic review of 12 observational studies involving 3,733,499 women (219,357 exposed), drug‑only ovulation induction was associated with a hazard ratio of 1.39 (95% CI 1.01‑1.92) for melanoma, while ART/IVF showed a near‑null hazard ratio of 1.09 (95% CI 0.81‑1.48).
    Bottom line
    Drug‑only ovulation induction may increase melanoma risk (HR 1.39, 95% CI 1.01‑1.92), whereas ART/IVF does not show a clear association (HR 1.09, 95% CI 0.81‑1.48).

    PubMed, PMID 42924873

Summaries are written by AI from PubMed abstracts, for keeping up with the literature. Check the source before it changes care. Editorial policy · Medical disclaimer

Get Dermatology research every morning.

Free. Choose your Dermatology topics after you subscribe.